Participated · Series A · Aug 2026

Remepy develops Hybrid Drugs that integrate prescription medicines with personalized, AI-driven therapeutic apps to combine pharmacology with adaptive physical, cognitive, and behavioral interventions. The company partners with pharmaceutical firms to co-develop these drug–software combination products and recently announced a strategic collaboration with Merck KGaA. Remepy’s lead program, Hybridopa for Parkinson’s disease, produced encouraging Phase IIa results supported by peer‑reviewed publications and is being prepared for a global Phase III trial expected to begin in Q4 2026. The Series A financing and existing investor base have brought total capital raised to $62 million, providing funds to expand the company’s pipeline, platform, and pharmaceutical partnerships. Remepy positions its approach within emerging FDA frameworks for drug‑software combination products and aims to create new IP and lifecycle-management opportunities for partner drugs.

Participated · Seed · May 2026

bitBiome develops a data-driven platform for bio-manufacturing centered on its single-cell microbial genome sequencing technology (bit-MAP®) and a proprietary microbial gene database (bit-GEM) that has grown from 2 billion to over 3 billion genes. The company pairs bioinformatics, machine learning/AI, and high-throughput screening including robotics to enable enzyme discovery, enzyme and metabolic-pathway design, and microbial strain engineering via platforms such as bit-QED and bit-EVO. It has expanded leadership with experienced global hires and forged commercial partnerships and CMO ties to support end-to-end research-to-manufacturing workflows, including collaborations with Tojo Vikas International, Kyoritsu Seiyaku, and Sanwa Starch. bitBiome has been selected for large public projects (e.g., NEDO) and published research using bit-MAP® with multiple research groups, and has begun U.S. sampling to expand its database. The company plans to use recent funding to further grow bit-GEM, advance its SENS-AI genome-biology model, expand labs for data collection, and scale global business development, and has reported cumulative funding of about ¥7.0 billion.

Participated · Equity · Nov 2025

Luup provides the LUUP micromobility sharing service, allowing users to rent electric scooters and bicycles from more than 15,500 ports across Japan. The company has recorded over 5 million app downloads, numbers it says rank among the country’s largest for micromobility platforms. In August, Luup unveiled the “Unimo,” a compact three-wheeled universal car aimed at broadening accessibility to its short-distance transport options regardless of users’ age or gender. Management intends to keep expanding port density, increase vehicle fleets, and roll out operations in additional areas while working closely with police and local governments on safety initiatives. Newly secured capital will be directed toward safety measures, traffic-rule education, port expansion, service improvements and geographic growth. With the latest round, Luup’s cumulative funding has reached approximately ¥21.4 billion, reflecting strong financial backing from both equity investors and major Japanese banks.

Participated · Series B · May 2024

Honeycomb uses an AI-driven platform that ingests hundreds of data points—geospatial datasets, aerial imagery, and building history—to price multi-unit residential risks without physical inspections. Its underwriting approach allows the company to offer premiums it says can be up to 40% cheaper for well-maintained buildings compared with traditional carriers. Customers include landlords, condo associations, and HOA boards managing multifamily housing. Honeycomb was co-founded in 2019 by CEO Itai Ben-Zaken and CTO Nimrod Sadot. The company reported it was cash-flow positive and profitable, ending 2025 with $275 million in gross written premium and more than $100 billion in total insured value across 22 states. Management projects crossing $500 million in GWP in the next couple of years as it scales the business.

Participated · Series D · Mar 2024

EV Motors Japan designs, builds and sells commercial electric vehicles—including buses, trucks, trikes and special vehicles—and is developing Level 4 autonomous buses. The company also offers charging equipment, maintenance, leasing/rental and ESCO services, and engages in battery and PV‑based renewable energy businesses. Recent fundraising will support construction of a final assembly plant (phase 2), procurement for received and anticipated bulk orders, prototype and demo vehicle development, and organizational strengthening. The company reports paid‑in capital of ¥6,570,200,000 as of June 28, 2024 and total historical fundraising of roughly ¥6.56 billion. EV Motors Japan intends to expand its mass‑production capability and vehicle lineup to accelerate market adoption and advance toward a zero‑emission society. EVモーターズ・ジャパン designs, manufactures and sells electric vehicles and charging solutions, including buses, trucks, trikes and special-purpose vehicles, and is developing Level 4 autonomous buses. The company also offers leasing, rental, ESCO services and renewable-energy businesses using batteries and PV. It intends to use recent funding to build a commercial EV final assembly factory (phase 2), finance vehicle procurement for orders, and support prototype and demo-vehicle development and organizational strengthening. The company reported a capital base of ¥6,375,200,000 as of March 29, 2024 and has raised a total of approximately ¥6.36 billion across all rounds. Founded in April 2019 and headquartered in Kitakyushu, Fukuoka, EVモーターズ・ジャパン is continuing a Series D fundraising process and plans further public announcements.